1
|
Jian-Bo T, Xing Z, Shuai B, Ding L, Tian-Hao W. Topomer CoMFA and HQSAR Study on Benzimidazole Derivative as NS5B Polymerase Inhibitor. LETT DRUG DES DISCOV 2022. [DOI: 10.2174/1570180818666210804125607] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Background:
In recent years, the number of people infected with the hepatitis C virus
(HCV) is increasing rapidly. This has become a major threat to global health, therefore, new anti-
HCV drugs are urgently needed. HCV NS5B polymerase is an RNA-dependent RNA polymerase
(RdRp), which plays an important role in virus replication, and can effectively prevent the replication
of HCV sub-genomic RNA in daughter cells. It is considered a very promising HCV therapeutic
target for the design of anti-HCV drugs.
Methods:
In order to explore the relationship between the structure of benzimidazole derivative and
its inhibitory activity on NS5B polymerase, holographic quantitative structure-activity relationship
(HQSAR) and Topomer comparative molecular field analysis (CoMFA) were used to establish benzimidazole
QSAR model of derivative inhibitors.
Results:
The results show that for the Topomer CoMFA model, the cross-validation coefficient q2
value is 0.883, and the non-cross-validation coefficient r2 value is 0.975. The model is reasonable,
reliable, and has a good predictive ability. For the HQSAR model, the cross-validated q2 value is
0.922, and the uncross-validated r2 value is 0.971, indicating that the model data fit well and has a
high predictive ability. Through the analysis of the contour map and color code diagram, 40 new
benzimidazole inhibitor molecules were designed, and all of them have higher activity than template
molecules, and the new molecules have significant interaction sites with protein 3SKE.
Conclusion:
The 3D-QSAR model established by Topomer CoMFA and HQSAR has good prediction
results and the statistical verification is valid. The newly designed molecules and docking results
provide theoretical guidance for the synthesis of new NS5B polymerase inhibitors and for the identification
of key residues that the inhibitors bind to NS5B, which helps to better understand their inhibitory
mechanism. These findings are helpful for the development of new anti-HCV drugs.
Collapse
Affiliation(s)
- Tong Jian-Bo
- College of Chemistry and Chemical Engineering, Shaanxi University of Science and Technology, Xi\'an 710021, China
- Shaanxi Key Laboratory of Chemical Additives for Industry, Xi\'an, 710021, China
| | - Zhang Xing
- College of Chemistry and Chemical Engineering, Shaanxi University of Science and Technology, Xi\'an 710021, China
- Shaanxi Key Laboratory of Chemical Additives for Industry, Xi\'an, 710021, China
| | - Bian Shuai
- College of Chemistry and Chemical Engineering, Shaanxi University of Science and Technology, Xi\'an 710021, China
- Shaanxi Key Laboratory of Chemical Additives for Industry, Xi\'an, 710021, China
| | - Luo Ding
- College of Chemistry and Chemical Engineering, Shaanxi University of Science and Technology, Xi\'an 710021, China
- Shaanxi Key Laboratory of Chemical Additives for Industry, Xi\'an, 710021, China
| | - Wang Tian-Hao
- College of Chemistry and Chemical Engineering, Shaanxi University of Science and Technology, Xi\'an 710021, China
- Shaanxi Key Laboratory of Chemical Additives for Industry, Xi\'an, 710021, China
| |
Collapse
|
2
|
Ganesan A, Barakat K. Applications of computer-aided approaches in the development of hepatitis C antiviral agents. Expert Opin Drug Discov 2017; 12:407-425. [PMID: 28164720 DOI: 10.1080/17460441.2017.1291628] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
INTRODUCTION Hepatitis C virus (HCV) is a global health problem that causes several chronic life-threatening liver diseases. The numbers of people affected by HCV are rising annually. Since 2011, the FDA has approved several anti-HCV drugs; while many other promising HCV drugs are currently in late clinical trials. Areas covered: This review discusses the applications of different computational approaches in HCV drug design. Expert opinion: Molecular docking and virtual screening approaches have emerged as a low-cost tool to screen large databases and identify potential small-molecule hits against HCV targets. Ligand-based approaches are useful for filtering-out compounds with rich physicochemical properties to inhibit HCV targets. Molecular dynamics (MD) remains a useful tool in optimizing the ligand-protein complexes and understand the ligand binding modes and drug resistance mechanisms in HCV. Despite their varied roles, the application of in-silico approaches in HCV drug design is still in its infancy. A more mature application should aim at modelling the whole HCV replicon in its active form and help to identify new effective druggable sites within the replicon system. With more technological advancements, the roles of computer-aided methods are only going to increase several folds in the development of next-generation HCV drugs.
Collapse
Affiliation(s)
- Aravindhan Ganesan
- a Faculty of Pharmacy and Pharmaceutical Sciences , University of Alberta , Edmonton , Canada
| | - Khaled Barakat
- a Faculty of Pharmacy and Pharmaceutical Sciences , University of Alberta , Edmonton , Canada
| |
Collapse
|
3
|
Wichapong K, Alard JE, Ortega-Gomez A, Weber C, Hackeng TM, Soehnlein O, Nicolaes GAF. Structure-Based Design of Peptidic Inhibitors of the Interaction between CC Chemokine Ligand 5 (CCL5) and Human Neutrophil Peptides 1 (HNP1). J Med Chem 2016; 59:4289-301. [PMID: 26871718 DOI: 10.1021/acs.jmedchem.5b01952] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Protein-protein interactions (PPIs) are receiving increasing interest, much sparked by the realization that they represent druggable targets. Recently, we successfully developed a peptidic inhibitor, RRYGTSKYQ ("SKY" peptide), that shows high potential in vitro and in vivo to interrupt a PPI between the platelet-borne chemokine CCL5 and the neutrophil-derived granule protein HNP1. This PPI plays a vital role in monocyte adhesion, representing a key mechanism in acute and chronic inflammatory diseases. Here, we present extensive and detailed computational methods applied to develop the SKY peptide. We combined experimentally determined binding affinities (KD) of several orthologs of CCL5 with HNP1 with in silico studies to identify the most likely heterodimeric CCL5-HNP1 complex which was subsequently used as a starting structure to rationally design peptidic inhibitors. Our method represents a fast and simple approach that can be widely applied to determine other protein-protein complexes and moreover to design inhibitors or stabilizers of protein-protein interaction.
Collapse
Affiliation(s)
- Kanin Wichapong
- Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University , 6200 MD Maastricht, The Netherlands
| | - Jean-Eric Alard
- Institute for Cardiovascular Prevention, Ludwig Maximilians University Munich , 80336 Munich, Germany
| | - Almudena Ortega-Gomez
- Institute for Cardiovascular Prevention, Ludwig Maximilians University Munich , 80336 Munich, Germany
| | - Christian Weber
- Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University , 6200 MD Maastricht, The Netherlands.,Institute for Cardiovascular Prevention, Ludwig Maximilians University Munich , 80336 Munich, Germany.,German Centre for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, 80336 Munich, Germany
| | - Tilman M Hackeng
- Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University , 6200 MD Maastricht, The Netherlands
| | - Oliver Soehnlein
- Institute for Cardiovascular Prevention, Ludwig Maximilians University Munich , 80336 Munich, Germany.,German Centre for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, 80336 Munich, Germany.,Department of Pathology, Academic Medical Center (AMC), University of Amsterdam , 1105 AZ Amsterdam, The Netherlands
| | - Gerry A F Nicolaes
- Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University , 6200 MD Maastricht, The Netherlands
| |
Collapse
|